Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model

Tatiana Lobo, S. Konig, D. E. Machado, L. E. Nasciutti, M. F. Forni, I. M.B. Francischetti, M. C. Sogayar, R. Q. Monteiro

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background: The expression levels of the clotting initiator protein Tissue Factor (TF) correlate with vessel density and the histological malignancy grade of glioma patients. Increased procoagulant tonus in high grade tumors (glioblastomas) also indicates a potential role for TF in progression of this disease, and suggests that anticoagulants could be used as adjuvants for its treatment. Objectives: We hypothesized that blocking of TF activity with the tick anticoagulant Ixolaris might interfere with glioblastoma progression. Methods and results: TF was identified in U87-MG cells by flow-cytometric and functional assays (extrinsic tenase). In addition, flow-cytometric analysis demonstrated the exposure of phosphatidylserine in the surface of U87-MG cells, which supported the assembly of intrinsic tenase (FIXa/FVIIIa/FX) and prothrombinase (FVa/FXa/prothrombin) complexes, accounting for the production of FXa and thrombin, respectively. Ixolaris effectively blocked the in vitro TF-dependent procoagulant activity of the U87-MG human glioblastoma cell line and attenuated multimolecular coagulation complexes assembly. Notably, Ixolaris inhibited the in vivo tumorigenic potential of U87-MG cells in nude mice, without observable bleeding. This inhibitory effect of Ixolaris on tumor growth was associated with downregulation of VEGF and reduced tumor vascularization. Conclusion: Our results suggest that Ixolaris might be a promising agent for anti-tumor therapy in humans.

Original languageEnglish
Pages (from-to)1855-1864
Number of pages10
JournalJournal of Thrombosis and Haemostasis
Volume7
Issue number11
DOIs
Publication statusPublished - 1 Nov 2009
Externally publishedYes

Fingerprint

Thromboplastin
Glioblastoma
cancer procoagulant
Growth
Neoplasms
Anticoagulants
Phosphatidylserines
Ticks
Nude Mice
Thrombin
Glioma
Vascular Endothelial Growth Factor A
Disease Progression
Down-Regulation
Hemorrhage
Cell Line
Therapeutics
Proteins

Keywords

  • Angiogenesis
  • Anticoagulant therapy
  • Glioblastoma
  • Ixolaris
  • Primary tumor growth
  • Tissue factor

ASJC Scopus subject areas

  • Hematology

Cite this

Lobo, T., Konig, S., Machado, D. E., Nasciutti, L. E., Forni, M. F., Francischetti, I. M. B., ... Monteiro, R. Q. (2009). Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. Journal of Thrombosis and Haemostasis, 7(11), 1855-1864. https://doi.org/10.1111/j.1538-7836.2009.03553.x

Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. / Lobo, Tatiana; Konig, S.; Machado, D. E.; Nasciutti, L. E.; Forni, M. F.; Francischetti, I. M.B.; Sogayar, M. C.; Monteiro, R. Q.

In: Journal of Thrombosis and Haemostasis, Vol. 7, No. 11, 01.11.2009, p. 1855-1864.

Research output: Contribution to journalArticle

Lobo, T, Konig, S, Machado, DE, Nasciutti, LE, Forni, MF, Francischetti, IMB, Sogayar, MC & Monteiro, RQ 2009, 'Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model', Journal of Thrombosis and Haemostasis, vol. 7, no. 11, pp. 1855-1864. https://doi.org/10.1111/j.1538-7836.2009.03553.x
Lobo, Tatiana ; Konig, S. ; Machado, D. E. ; Nasciutti, L. E. ; Forni, M. F. ; Francischetti, I. M.B. ; Sogayar, M. C. ; Monteiro, R. Q. / Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. In: Journal of Thrombosis and Haemostasis. 2009 ; Vol. 7, No. 11. pp. 1855-1864.
@article{ad622854f6ba49f29795fbc1e7fd9cdf,
title = "Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model",
abstract = "Background: The expression levels of the clotting initiator protein Tissue Factor (TF) correlate with vessel density and the histological malignancy grade of glioma patients. Increased procoagulant tonus in high grade tumors (glioblastomas) also indicates a potential role for TF in progression of this disease, and suggests that anticoagulants could be used as adjuvants for its treatment. Objectives: We hypothesized that blocking of TF activity with the tick anticoagulant Ixolaris might interfere with glioblastoma progression. Methods and results: TF was identified in U87-MG cells by flow-cytometric and functional assays (extrinsic tenase). In addition, flow-cytometric analysis demonstrated the exposure of phosphatidylserine in the surface of U87-MG cells, which supported the assembly of intrinsic tenase (FIXa/FVIIIa/FX) and prothrombinase (FVa/FXa/prothrombin) complexes, accounting for the production of FXa and thrombin, respectively. Ixolaris effectively blocked the in vitro TF-dependent procoagulant activity of the U87-MG human glioblastoma cell line and attenuated multimolecular coagulation complexes assembly. Notably, Ixolaris inhibited the in vivo tumorigenic potential of U87-MG cells in nude mice, without observable bleeding. This inhibitory effect of Ixolaris on tumor growth was associated with downregulation of VEGF and reduced tumor vascularization. Conclusion: Our results suggest that Ixolaris might be a promising agent for anti-tumor therapy in humans.",
keywords = "Angiogenesis, Anticoagulant therapy, Glioblastoma, Ixolaris, Primary tumor growth, Tissue factor",
author = "Tatiana Lobo and S. Konig and Machado, {D. E.} and Nasciutti, {L. E.} and Forni, {M. F.} and Francischetti, {I. M.B.} and Sogayar, {M. C.} and Monteiro, {R. Q.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1111/j.1538-7836.2009.03553.x",
language = "English",
volume = "7",
pages = "1855--1864",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model

AU - Lobo, Tatiana

AU - Konig, S.

AU - Machado, D. E.

AU - Nasciutti, L. E.

AU - Forni, M. F.

AU - Francischetti, I. M.B.

AU - Sogayar, M. C.

AU - Monteiro, R. Q.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Background: The expression levels of the clotting initiator protein Tissue Factor (TF) correlate with vessel density and the histological malignancy grade of glioma patients. Increased procoagulant tonus in high grade tumors (glioblastomas) also indicates a potential role for TF in progression of this disease, and suggests that anticoagulants could be used as adjuvants for its treatment. Objectives: We hypothesized that blocking of TF activity with the tick anticoagulant Ixolaris might interfere with glioblastoma progression. Methods and results: TF was identified in U87-MG cells by flow-cytometric and functional assays (extrinsic tenase). In addition, flow-cytometric analysis demonstrated the exposure of phosphatidylserine in the surface of U87-MG cells, which supported the assembly of intrinsic tenase (FIXa/FVIIIa/FX) and prothrombinase (FVa/FXa/prothrombin) complexes, accounting for the production of FXa and thrombin, respectively. Ixolaris effectively blocked the in vitro TF-dependent procoagulant activity of the U87-MG human glioblastoma cell line and attenuated multimolecular coagulation complexes assembly. Notably, Ixolaris inhibited the in vivo tumorigenic potential of U87-MG cells in nude mice, without observable bleeding. This inhibitory effect of Ixolaris on tumor growth was associated with downregulation of VEGF and reduced tumor vascularization. Conclusion: Our results suggest that Ixolaris might be a promising agent for anti-tumor therapy in humans.

AB - Background: The expression levels of the clotting initiator protein Tissue Factor (TF) correlate with vessel density and the histological malignancy grade of glioma patients. Increased procoagulant tonus in high grade tumors (glioblastomas) also indicates a potential role for TF in progression of this disease, and suggests that anticoagulants could be used as adjuvants for its treatment. Objectives: We hypothesized that blocking of TF activity with the tick anticoagulant Ixolaris might interfere with glioblastoma progression. Methods and results: TF was identified in U87-MG cells by flow-cytometric and functional assays (extrinsic tenase). In addition, flow-cytometric analysis demonstrated the exposure of phosphatidylserine in the surface of U87-MG cells, which supported the assembly of intrinsic tenase (FIXa/FVIIIa/FX) and prothrombinase (FVa/FXa/prothrombin) complexes, accounting for the production of FXa and thrombin, respectively. Ixolaris effectively blocked the in vitro TF-dependent procoagulant activity of the U87-MG human glioblastoma cell line and attenuated multimolecular coagulation complexes assembly. Notably, Ixolaris inhibited the in vivo tumorigenic potential of U87-MG cells in nude mice, without observable bleeding. This inhibitory effect of Ixolaris on tumor growth was associated with downregulation of VEGF and reduced tumor vascularization. Conclusion: Our results suggest that Ixolaris might be a promising agent for anti-tumor therapy in humans.

KW - Angiogenesis

KW - Anticoagulant therapy

KW - Glioblastoma

KW - Ixolaris

KW - Primary tumor growth

KW - Tissue factor

UR - http://www.scopus.com/inward/record.url?scp=70449455562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449455562&partnerID=8YFLogxK

U2 - 10.1111/j.1538-7836.2009.03553.x

DO - 10.1111/j.1538-7836.2009.03553.x

M3 - Article

VL - 7

SP - 1855

EP - 1864

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 11

ER -